Allos Therapeutics Announces Preliminary Data from Phase 1 Study of PDX in patients with relapsed or refractory cutaneous T-cell lymphomaAllos Therapeutics, Inc. announced the presentation of preliminary data from the Phase 1 study of PDX with vitamin B12 and folic acid in patients with relapsed or refractory cutaneous T-cell lymphoma , at the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland, June 4-7. www.tadalafilgroup.com
About PDX PDX is a novel, retention.ecule chemotherapeutic agent that inhibits dihydrofolate reductase , or DHFR, a folic acid -dependent enzyme involved in the building of nucleic acid, or DNA, and other processes. PDX was rationally designed for the efficient transport in tumor cells via the reduced folate carrier, or RFC-1 and effective intracellular drug retention. The Company believes these biochemical features, together with the preclinical and clinical data in a variety of tumors, suggest that PDX may have a favorable safety and efficacy profile to methotrexate and certain other DHFR inhibitors. The FDA has Drug status Drug status and Fast Track designation PDX for the treatment of patients with T-cell lymphoma.
Hemangioma of most of the hazard can be increase malformations , mild.